Beyond Filters: ADMET Risk™ for Multi-objective Drug Development

Beyond Filters: ADMET Risk™ for Multi-objective Drug Development

Conference: ACS
Software: ADMET Predictor®
Division: PBPK

We calculated predictions for over 30 properties relevant to absorption, distribution, metabolism, excretion and toxicity (ADMET) for a large and pharmaceutically pertinent...

The biowaivers extension for BCS Class III drugs: the effect of dissolution rate on on the bioequivalence of BCS Class III IR drugs predicted by computer simulation

The biowaivers extension for BCS Class III drugs: the effect of dissolution rate on on the bioequivalence of BCS Class III IR drugs predicted by computer simulation

Authors: Tsume Y, Amidon GL
Publication: Mol Pharm
Software: GastroPlus®

The Biopharmaceutical Classification System (BCS) guidance issued by the FDA allows waivers for in vivo bioavailability and bioequivalence studies for immediate-release...

In Silico Classification of Major Clearance Pathways of Drugs with Their Physiochemical Parameters

In Silico Classification of Major Clearance Pathways of Drugs with Their Physiochemical Parameters

Publication: Drug Metab Dispos
Software: ADMET Predictor®

Predicting major clearance pathways of drugs is important in understanding their pharmacokinetic properties in clinical use, such as drug-drug interactions and genetic...

Plasma pharmacokinetics of two consecutive doses of ferumoxytol in healthy subjects

Plasma pharmacokinetics of two consecutive doses of ferumoxytol in healthy subjects

Publication: Clin Pharmacol Ther

Intravenous (IV) iron is used to treat iron-deficiency anemia in patients with chronic kidney disease (CKD). Ferumoxytol is a novel iron formulation administered rapidly as two IV boluses of 510 mg each. In this placebo-controlled, double-blind...

Improving productivity with model-based drug development: an enterprise perspective

Improving productivity with model-based drug development: an enterprise perspective

Authors: Grasela TH, Slusser R
Publication: Clin Pharmacol Ther

The productivity of the pharma enterprise has fallen, as evidenced by a decline in regulatory submissions and less commercial success.

Physiologically-Based Pharmacokinetic (PBPK) Modeling of Diltiazem-Midazolam Drug-Drug Interaction (DDI)

Physiologically-Based Pharmacokinetic (PBPK) Modeling of Diltiazem-Midazolam Drug-Drug Interaction (DDI)

Conference: DDI
Division: PBPK

The purpose of this modeling effort was to explore the effects of various processes and physiological parameters on the DDI involving competitive and time-dependent inhibition (TDI). Absorption and…